These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 31094589)

  • 21. Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
    Aapro M; Jordan K; Scotté F; Celio L; Karthaus M; Roeland E
    Curr Cancer Drug Targets; 2022; 22(10):806-824. PubMed ID: 35570542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
    Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
    Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
    Hesketh PJ; Rossi G; Rizzi G; Palmas M; Alyasova A; Bondarenko I; Lisyanskaya A; Gralla RJ
    Ann Oncol; 2014 Jul; 25(7):1340-1346. PubMed ID: 24608196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
    Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
    BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
    Schwartzberg L; Karthaus M; Rossi G; Rizzi G; Borroni ME; Rugo HS; Jordan K; Hansen V
    Cancer Med; 2019 May; 8(5):2064-2073. PubMed ID: 30968588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy.
    Nelson WW; Vaidya V; Scott JA; Wang B; Lambert H; Holmes B; Bailey WL
    Future Oncol; 2023 Jan; 19(1):29-36. PubMed ID: 36622264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
    Rugo HS; Rossi G; Rizzi G; Aapro M
    Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
    Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
    Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Zelek L; Navari R; Aapro M; Scotté F
    Cancer Med; 2023 Aug; 12(15):15769-15776. PubMed ID: 37537943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NEPA as antiemetic prophylaxis after failure of 5HT
    Valerio MR; Gebbia V; Borsellino N; Vecchia M; Serretta V; Pardo S; Cipolla C; Galanti D
    J Oncol Pharm Pract; 2021 Apr; 27(3):609-613. PubMed ID: 32507099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
    Hesketh PJ; Palmas M; Nicolas P
    Support Care Cancer; 2018 Apr; 26(4):1151-1159. PubMed ID: 29080920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
    Aapro M; Karthaus M; Schwartzberg L; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Hansen V; Rossi G; Rizzi G; Borroni ME; Rugo H
    Support Care Cancer; 2017 Apr; 25(4):1127-1135. PubMed ID: 27885469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK
    Bošnjak SM; Gralla RJ; Schwartzberg L
    Support Care Cancer; 2017 May; 25(5):1661-1671. PubMed ID: 28108820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.
    Md Yusof M; Abdullah MM; Yap BK; Ng SC; Low JSH; Lam KS; Ahmad Badruddin RBA; Lai CNB; Lau KL; Chong KJ; Nonis JG; Ahmad Annuar MA; Abdul Rahman MHFB
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):419-427. PubMed ID: 34811924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
    Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
    Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
    Schwartzberg L; Roeland E; Andric Z; Kowalski D; Radic J; Voisin D; Rizzi G; Navari R; Gralla RJ; Karthaus M
    Ann Oncol; 2018 Jul; 29(7):1535-1540. PubMed ID: 29722791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.
    Badalamenti G; Incorvaia L; Messina C; Musso E; Casarin A; Ricciardi MR; De Luca I; Bazan V; Russo A
    Support Care Cancer; 2019 Sep; 27(9):3593-3597. PubMed ID: 30762142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fixed Combination Antiemetic: A Literature Review on Prevention of Chemotherapy-Induced Nausea and Vomiting Using Netupitant/Palonosetron.
    Clark-Snow RA; Vidall C; Börjeson S; Jahn P
    Clin J Oncol Nurs; 2018 Apr; 22(2):E52-E63. PubMed ID: 29547597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
    Navari RM; Nelson WW; Shoaib S; Singh R; Zhang W; Bailey WL
    Adv Ther; 2023 Jul; 40(7):3217-3226. PubMed ID: 37245189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK.
    Cawston H; Bourhis F; Eriksson J; Ruffo P; D'Agostino P; Turini M; Schwartzberg L; McGuire A
    Drugs Context; 2017; 6():212298. PubMed ID: 28392826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.